-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Tyrphostin 9
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/10537-47-0.gif)
| Category | Influenza Virus |
| CAS | 10537-47-0 |
| Description | Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM. |
Product Information
| Synonyms | SF 6847; RG 50872; SF6847; RG50872; SF-6847; RG-50872 |
| IUPAC Name | 2-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]propanedinitrile |
| Molecular Weight | 282.38 |
| Molecular Formula | C18H22N2O |
| Canonical SMILES | CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C(C#N)C#N |
| InChI | InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3 |
| InChIKey | MZOPWQKISXCCTP-UHFFFAOYSA-N |
| Boiling Point | 386.8±37.0 °C at 760 mmHg |
| Melting Point | 141-143 °C (ethanol) |
| Flash Point | 187.7±26.5 °C |
| Purity | >98% |
| Density | 1.1±0.1 g/cm3 |
| Solubility | In Vitro: DMSO: ≥ 100 mg/mL (354.13 mM); H2O: < 0.1 mg/mL (insoluble) |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Keep container tightly closed in a dry and well-ventilated place. (2 years) |
| Complexity | 459 |
| Exact Mass | 282.173213330 |
| Index Of Refraction | 1.555 |
| In Vitro | Tyrphostin A9 inhibited TNF-induced tyrosine phosphorylation of pyk2 without blocking the cells' bactericidal activity Tyrphostin A9 is a PDGF receptor tyrosine kinase inhibitor (IC50 = 500 nM). Recent findings suggest that signaling via PDGF receptor tyrosine kinases is not necessary for the shift of the smooth muscle cells from a contractile to a synthetic phenotype. On the other hand these enzymes apparently carry out important functions in the control of intracellular membrane traffic and cell division. |
| In Vivo | Tyrphostin A9 inhibited TNF-induced tyrosine phosphorylation of pyk2 without blocking the cells' bactericidal activity. |
| PSA | 67.81000 |
| Target | VEGFR; Influenza Virus; PDGFR |
| Vapor Pressure | 0.0±0.9 mmHg at 25°C |
| XLogP3-AA | 5 |
